Elective surgeries, including bariatric surgery, were restricted during the pandemic, and the willingness to seek medical treatment also changed. The number of patients with obesity who underwent surgery was significantly reduced. According to an article published by PubMed Central in March 2022, a study was conducted in North America, which showed that there was a 12.1% reduction in total bariatric surgery cases and a 13.8% reduction in bariatric surgery cases per center. Thus, the COVID-19 pandemic significantly impacted the market initially, however as the pandemic has currently subsided, bariatric surgery procedures are taking place normally, hence the studied market is expected to have stable growth during the forecast period of the study.
Factors such as the increase in obesity patients, the high prevalence of type-2 diabetes and heart diseases, and increasing public awareness about bariatric surgery and government initiatives to curb obesity are expected to boost the market's growth during the forecast period of the study.
The increasing prevalence of obesity is a major factor driving the growth of the market, as bariatric surgery is majorly performed on obese patients. For instance, according to the data published by Trust for America's Health in September 2022, it was estimated that nationally 41.9% of adults had obesity in the United States in 2021, out of which black adults had the highest level of adult obesity at 49.9 percent, Hispanic adults had an obesity rate of 45.6 percent, white adults had an obesity rate of 41.4 percent, Asian adults had an obesity rate of 16.1 percent, and rural parts of the country had higher rates of obesity than urban and suburban areas. Thus, the high prevalence of obesity is expected to boost the market growth.
As diabetes and cardiovascular diseases are major risk factors in obese patients, the rising prevalence of these diseases is also expected to boost market growth. For instance, according to the data published by Diabetes Canada in February 2022, it is estimated that 30% of Canadians live with diabetes or prediabetes. The source also stated that approximately 5,719,000 Canadians were living with type 1 diabetes, type 2 diagnosed diabetes, and type 2 undiagnosed diabetes in 2022, and this number is expected to reach 7,277,000 by 2032. Thus, the high prevalence of diabetes is also expected to boost the market growth.
Moreover, increasing product launches by key market players are also boosting the market growth. For instance, in May 2021, Standard Bariatrics launched its novel Titan SGS stapling technology, specifically designed for bariatric sleeve surgery. Also, the device has been cleared by the United States FDA.
Therefore, the aforementioned factors, such as the rising prevalence of obesity, the rising prevalence of diabetes and cardiovascular diseases, and the increasing product launches, are expected to boost market growth. However, the high cost of surgery is expected to impede the market growth during the forecast period of the study.
North America Bariatric Surgery Market Trends
Closure Device Segment is Expected to Experience Significant Growth Over the Forecast Period
Closure devices are used for reconnecting the tissues during surgical procedures and for closing incisions made by trocars. The laparoscopic port closure device successfully and safely closes the port sites in obese patients undergoing bariatric procedures and surgeries. These operations are performed with specialized instruments designed to be inserted through small incisions. Therefore, the rising number of laparoscopic gastric bypass (GBP) surgery procedures helps increase the usage of closure devices. Moreover, the rising prevalence of obesity and the rising prevalence of type 2 diabetes, and cardiovascular diseases are also expected to boost segment growth.According to an article updated by NCBI in September 2022, laparoscopic gastric bypass surgery is considered to be one of the most popular weight loss surgeries in the United States of America. It has clear benefits over the traditional open approach in terms of cost and patient satisfaction with similar successes. Patients can expect to have approximately 60% excess weight loss and an exceptional long-term resolution of obesity-related comorbidities after laparoscopic gastric bypass. Thus, the increasing advantages of laparoscopic gastric bypass surgery are expected to boost the usage of closure devices during the forecast period of the study.
Furthermore, the rising prevalence of obesity in the region is also expected to boost the usage of closure devices for bariatric surgeries. For instance, according to the data published by Statistics Canada in August 2022, it has been estimated that around 2,398,200 (30.8%) people of age in between 18 to 34 years were overweight in 2021, and 1,727,000 (22.2%) people aged between 18 to 34 years were obese in 2021. Thus, the high prevalence of obesity in the region is also expected to boost segment growth.
Therefore, the aforementioned factors, such as the increasing advantages of laparoscopic gastric bypass surgery and the rising prevalence of obesity, are expected to boost segment growth during the forecast period of the study.
United States is Expected to Hold a Significant Market Share Over the Forecast Period
The bariatric surgery market in the United States is mainly driven by the increasing use of advanced technology in healthcare systems, increasing developments by major market players, the rising prevalence of type 2 diabetes and cardiovascular diseases, and the country's rising burden of obesity.The increasing burden of obesity in the country is a major factor driving market growth. For instance, according to the data published by Dialogues économiques in March 2022, approximately 75% of Mexico's adult population is either obese or overweight, which makes it one of the world's leading countries in both adult and childhood obesity. Thus, the increasing burden of obesity is expected to increase bariatric surgeries as well, resulting in market growth.
Moreover, the increasing prevalence of diabetes and cardiovascular diseases is also expected to boost the market growth. For instance, according to the data updated by CDC in June 2022, it was estimated that 37.3 million people would have diabetes in the United States in 2021, which accounts for 11.3% of the United States population.
Additionally, the rising product launches by key market players are expected to boost the market growth. For instance, in June 2021, Ethicon, part of the Johnson & Johnson Medical Devices Companies, launched the ENSEAL X1 Curved Jaw Tissue Sealer for colorectal, gynecological, bariatric surgery, and thoracic procedures. Moreover, in September 2021, Olympus America launched the POWER SEAL advanced bipolar surgical energy devices to strengthen its Surgical Portfolio. The POWER SEAL devices can be used in numerous forms of surgical intervention, including bariatric surgical procedures.
Therefore, the aforementioned factors, such as the increasing product launches and the rising prevalence of obesity, are expected to boost the market growth in the country during the forecast period of the study.
North America Bariatric Surgery Industry Overview
The North American bariatric surgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising number of obese patients, a few other smaller players are also expected to enter the market in the coming few years. Some of the major players in the market are Medtronic PLC, Ethicon Inc., Johnson and Johnson, B. Braun SE, Olympus Corporation, and Conmed Corporation, among others.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Medtronic PLC
- Johnson and Johnson
- Apollo Endosurgery Inc.
- Intuitive Surgical Inc.
- B. Braun SE
- Olympus Corporation
- CooperSurgical Inc.
- Teleflex Incorporated (Standard Bariatrics Inc.)
- Spatz Medical
- Conmed Corporation
Methodology
LOADING...